Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

[Yakuji Nippo]Technology strategies for practical use of biopharmaceuticals – Discussion at the review meeting in the next fiscal year

The Ministry of Economy, Trade and Industry (METI) will establish a "review meeting for life science technology strategies" to discuss...
  • Target market
    Japan
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine, Medical device, Digital health, Others
  • Business function
    Marketing >
  • Keyword
  • Author
    "LSMIP Editorial Office" of "CM Plus Corporation"
  • Availability
    Membership

Detail


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

 

METI
Technology strategies for practical use of biopharmaceuticals – Discussion at the review meeting in the next fiscal year

February 8th, 2021

The Ministry of Economy, Trade and Industry (METI) will establish a "review meeting for life science technology strategies" to discuss about necessary policies for practical use of biopharmaceuticals and regenerative medicine products in the next fiscal year. To enhance the competitive power of the Contract Manufacturing Organizations (CMOs)/Contract Development Manufacturing Organizations (CDMOs), their participation in this project will be promoted under the government's initiative to immediately cope with modalities and manufacturing methods of biopharmaceuticals.  The government intends to support  for biopharmaceutical CMOs/CDMOs in a particular to extend to gene/cell therapy product area that is expected to grow in the future. The strategies will be developed within the next fiscal year and then implemented as METI's policies from 2022.
 

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept